| Type 2 Diabetes Mellitus |
1 |
1 |
| Renal Failure |
0 |
0.94 |
| SGLT2 Inhibitor |
0 |
0.82 |
| Chronic Kidney Disease |
0 |
0.75 |
| Acute Kidney Injury |
0 |
0.46 |
| Kidney |
0 |
0.39 |
| Renal Disease |
0 |
0.37 |
| Urinary Tract Infection |
0 |
0.33 |
| Fractures |
0 |
0.23 |
| Amputation |
0 |
0.22 |
| Type 1 Diabetes Mellitus |
0 |
0.22 |
| Limb |
0 |
0.17 |
| Cardiovascular Risk Management |
0 |
0.12 |
| Heart Failure (HF) |
0 |
0.12 |
| Cardiovascular disease |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Hypoglycemia |
0 |
0.09 |
| Medicare |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.08 |
| GLP-1 Receptor Agonist |
0 |
0.07 |
| Health Insurance |
0 |
0.06 |